الفهرس 
EGFR, cancer and discovery of anti-EGFR therapiesOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
Identifying molecular agents inhibiting specific functions in cancer cell progression is considered one of the most successful plans in cancer treatment. The epidermal growth factor receptor (EGFR) over-activation is observed in many cancers. Therefore, targeting EGFR and its downstream signaling cascades is considered a rational and valuable approach in cancer therapy. It has been shown that the EGFR (HER1 and HER2) genes and members of the HER receptor family are overexpressed in breast cancer (MCF7). Also, EGFR overexpression has been found in 43-89% of instances of lung cancer (A549). Several synthetic EGFR tyrosine kinase inhibitors (TKIs) have been evaluated in recent years, mostly exhibiting clinical efficacy in relevant models and categorized into first, second, third, and fourth generation.